Insider Trade: Joanne Quan Unloaded 4,000 Shares of Eiger BioPharmaceuticals, Inc. (EIGR); Hess (HES) Has 0.94 Sentiment

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Sentiment for Hess Corp (HES)

Hess Corp (HES) investors sentiment increased to 0.94 in 2017 Q4. It’s up 0.06, from 0.88 in 2017Q3. The ratio is more positive, as 194 institutional investors started new or increased positions, while 206 cut down and sold stock positions in Hess Corp. The institutional investors in our database now hold: 256.03 million shares, up from 254.48 million shares in 2017Q3. Also, the number of institutional investors holding Hess Corp in top ten positions increased from 5 to 7 for an increase of 2. Sold All: 45 Reduced: 161 Increased: 131 New Position: 63.

Ratings analysis reveals 100% of Hess’s analysts are positive. Out of 2 Wall Street analysts rating Hess, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. HES was included in 2 notes of analysts from September 12, 2016. As per Thursday, December 8, the company rating was upgraded by JP Morgan. The stock of Hess Corporation (NYSE:HES) earned “Accumulate” rating by KLR Group on Monday, September 12.

Hess Corporation, an exploration and production company, develops, produces, purchases, transports, and sells crude oil, natural gas liquids, and natural gas. The company has market cap of $16.07 billion. The firm operates in two divisions, Exploration and Production, and Bakken Midstream. It currently has negative earnings. It is also involved in natural gas and crude oil gathering, processing of natural gas and the fractionation of natural gas liquids, transportation of crude oil by rail car, terminaling and loading natural gas and crude oil liquids, and the storage and terminating of propane primarily in the Bakken and Three Forks Shale plays in the Williston Basin area of North Dakota.

Marathon Asset Management Lp holds 8.54% of its portfolio in Hess Corporation for 471,000 shares. Key Group Holdings (Cayman) Ltd. owns 1.58 million shares or 6% of their US portfolio. Moreover, Central Securities Corp has 4.26% invested in the company for 560,000 shares. The Connecticut-based Impala Asset Management Llc has invested 3.86% in the stock. Levin Capital Strategies L.P., a New York-based fund reported 4.19 million shares.

Since January 1, 0001, it had 11 buys, and 15 selling transactions for $8.38 million activity.

The stock increased 1.11% or $0.56 during the last trading session, reaching $51.01. About 3.31 million shares traded. Hess Corporation (HES) has risen 8.91% since April 5, 2017 and is uptrending. It has underperformed by 2.64% the S&P500.

Analysts await Hess Corporation (NYSE:HES) to report earnings on April, 25. They expect $-0.54 EPS, up 49.53% or $0.53 from last year’s $-1.07 per share. After $-1.01 actual EPS reported by Hess Corporation for the previous quarter, Wall Street now forecasts -46.53% EPS growth.

Eiger Biopharmaceuticals Inc Chief Medical Officer Joanne Quan on the April 4, 2018 sold a total of 4,000 shares of the public company valued by the market at roughly $40,000 U.S. Dollars. This is based on an average price per share of $10.0 U.S. Dollars.

The stock increased 0.98% or $0.1 during the last trading session, reaching $10.35. About 64,106 shares traded. Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has declined 11.57% since April 5, 2017 and is downtrending. It has underperformed by 23.12% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on May, 11. They expect $-0.98 EPS, up 26.87% or $0.36 from last year’s $-1.34 per share. After $-1.11 actual EPS reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -11.71% EPS growth.

Hess Corporation (NYSE:HES) Institutional Positions Chart